Metabolic changes in patients with mitochondrial myopathies and effects of coenzyme Q10 therapy

Abstract We used a standardized bicycle ergometry protocol with a stepwise increasing workload (30–100 W) to evaluate various metabolic factors for the diagnosis and metabolic monitoring of mitochondrial encephalomyopathies. All patients (n = 9) showed pathological venous lactate/pyruvate (L/P) ratios, which normalized in three patients after 6 months of coenzyme Q10 (CoQ) therapy. Thus, the L/P ratio proved to be the clinically most useful parameter in the evaluation and monitoring of mitochondrial diseases, showing higher sensitivity than lactate measurements only. CoQ may exert a favourable effect in some patients with mitochondrial diseases.

[1]  D. Johns,et al.  Clinical Spectrum of Mitochondrial Diseases , 1996, Seminars in neurology.

[2]  Y. Wai,et al.  Overlapping syndrome of MERRF and MELAS: molecular and neuroradiological studies , 1993, Acta neurologica Scandinavica.

[3]  Margaret A. Johnson,et al.  Reversal of a mitochondrial DNA defect in human skeletal muscle , 1997, Nature Genetics.

[4]  N. Bresolin,et al.  Ubidecarenone in the treatment of mitochondrial myopathies: a multi-center double-blind trial , 1990, Journal of the Neurological Sciences.

[5]  P. Matthews,et al.  Combined aerobic training and dichloroacetate improve exercise capacity and indices of aerobic metabolism in muscle cytochrome oxidase deficiency , 1996, Neurology.

[6]  G Serratrice,et al.  31P NMR spectroscopy and ergometer exercise test as evidence for muscle oxidative performance improvement with coenzyme Q in mitochondrial myopathies , 1992, Neurology.

[7]  S. Dimauro,et al.  Mitochondrial encephalomyopathy with coenzyme Q10 deficiency , 1997, Neurology.

[8]  西川 嘉郎.  Treatment of Kearns-Sayre syndrome with coenzyme Q[10] , 1989 .

[9]  D. Turnbull,et al.  Presentation and clinical investigation of mitochondrial respiratory chain disease. A study of 51 patients. , 1995, Brain : a journal of neurology.

[10]  S Yorifuji,et al.  Long‐term coenzyme Q10 therapy for a mitochondrial encephalomyopathy with cytochrome c oxidase deficiency , 1989, Neurology.

[11]  P. Matthews,et al.  Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease , 1993, Neurology.

[12]  R. Rizzuto,et al.  Biological markers of oxidative stress in mitochondrial myopathies with progressive external ophthalmoplegia , 1991, Journal of the Neurological Sciences.

[13]  S. Yorifuji,et al.  Treatment of Kearns‐Sayre syndrome with coenzyme Q10 , 1986, Neurology.

[14]  R. Gold,et al.  Standardisierter Fahrradergometertest bei mitochondrialen Myopathien Indikation, Störfaktoren und klinisch aussagekräftige Parameter , 1998, Der Nervenarzt.

[15]  H. Reichmann,et al.  Phosphorus magnetic resonance spectroscopy in the evaluation of mitochondrial myopathies: results of a 6-month therapy study with coenzyme Q. , 1996, European neurology.

[16]  P. M. Matthews,et al.  Short‐term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders , 1995, Neurology.

[17]  Y. Mashima,et al.  Remission of Leber's hereditary optic neuropathy with idebenone , 1992, The Lancet.